Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin

Lancet

Volumn 350, Issue 9088, 1997, Pages 1363-1364

  Gottlieb, Jacob J ^b   Washenik, Ken ^b   Chachoua, Abraham ^b   Friedman Kien, Alvin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

AGED; ARTICLE; CASE REPORT; DRUG EFFICACY; EDEMA; ENCAPSULATION; FATIGUE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; SKIN ULCER;

EID: 0031573099     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)65133-1     Document Type: Article

References (5)

1. Bogner JR. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acq Immune Def Syndr 1994; 7: 463-68.
2. Wagner D, Kern WV, Kern P. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences. Clin Invest 1994; 72: 417-23.
3. Northfelt DW. Pharmokinetics, tumor localization and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc Am Soc Clin Oncol 1993; 12: 51.
4. Gabizon A. Prolonged circulation time and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-96.
5. Gregoriadis G, Florence A. Liposomal and cancer therapy. Cancer Cells 1991; 3: 144-46.